According to MarkNtel Advisors study the Global Next Generation Immunotherapy Market is projected to grow at a CAGR of around 7.5% during the forecast period, i.e., 2024-29.

“In case you missed it, we are currently revising our reports. Click on the below to get the most latest research data with forecast for years 2024 to 2030, including market size, industry trends, and competitive analysis. It wouldn't take long for the team to deliver the most recent version of the report.”    

Access Free Sample Report - https://www.marknteladvisors.com/query/request-sample/next-generation-immunotherapy-market.html

Key Findings of the Study: Next Generation Immunotherapy market

Global Next Generation Immunotherapy Market Driver:

Growing Adoption of Chimeric Antigen Receptor (CAR) T-cell Therapy – In recent years, there has been a high demand for chimeric antigen receptor (CAR) T-cell therapy, which has been majorly driven by the rising prevalence of relapsed B-cell acute lymphoblastic leukemia (ALL) and specific non-Hodgkin lymphomas. For instance,

  • In 2020, according to the GLOBOCON, non-Hodgkin lymphomas (NHL) have been ranked as one of the most common cancers and had an estimated 544,000 new cancer cases and 260,000 cancer deaths in 2020.

The rising demand for CAR-T cell therapy among NHL patients has been majorly attributed to the superior clinical outcomes of chimeric antigen receptor (CAR) T-cell therapy arising from its proven success in treating challenging conditions. In addition, to cater to this rising demand for CAR-T cell therapy, companies have heightened funding into CAR-T cell therapy research & development, which led to the launch of new drugs.

Global Next Generation Immunotherapy Market Challenge:

Reimbursement Challenges in the Global Next Generation Immunotherapy Market– The high costs associated with innovative therapies have been raising concerns regarding their affordability and reimbursement. The personalized and complex nature of next-generation immunotherapies has contributed to their high price tags, which were creating challenges for healthcare systems, payers, and patients in securing reimbursement and access. Reimbursement policies and mechanisms were not fully developed or adapted to account for the unique characteristics of these therapies, considering factors such as long-term patient outcomes, cost-effectiveness, and the potential for cure or prolonged remission. For instance,

  • In 2021, as per the Centres for Medicare & Medicaid Services (CMS), in the inpatient setting, the current reimbursement model for CAR-T therapy falls short of covering the high costs, leading to potential financial losses for hospitals treating Medicare patients.

One of the key issues with the current reimbursement model in the inpatient setting has been that it fails to account for the full cost spectrum of next-generation immunotherapies like CAR-T therapy, including the complex and resource-intensive care required for patient management. Hence, this financial strain has not only been impacting patient’s access to CAR-T therapy but has also been affecting the sales of next-generation immunotherapies across the globe.

For more detailed information about the Next Generation Immunotherapy market report, click here – https://www.marknteladvisors.com/research-library/next-generation-immunotherapy-market.html

Scope of the Report and Next Generation Immunotherapy Market Segmentation:

By Type

  • Vaccines- Market Size & Forecast 2019-2029F, USD Million
    • mRNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
    • DNA Vaccines- Market Size & Forecast 2019-2029F, USD Million
    • Protein Vaccines- Market Size & Forecast 2019-2029, USD Million
    • Others (Viral Vector Vaccines, Nanoparticle Vaccines, etc.)- Market Size & Forecast 2019-2029, USD Million
  • Immune Checkpoint Modulators- Market Size & Forecast 2019-2029F, USD Million
  • CAR-T Cell Therapy- Market Size & Forecast 2019-2029F, USD Million
  • Tumor-Infiltrating Lymphocytes (TILs) Therapy- Market Size & Forecast 2019-2029F, USD Million
  • Bispecific Antibodies- Market Size & Forecast 2019-2029F, USD Million
  • Oncolytic Virus Therapy- Market Size & Forecast 2019-2029F, USD Million
  • Others (Antibody-drug Conjugates, ACE Inhibitors, etc.)- Market Size & Forecast 2019-2029F, USD Million

By Route of Administration

  • Intravenous- Market Size & Forecast 2019-2029F, USD Million
  • Intratumoral- Market Size & Forecast 2019-2029F, USD Million
  • Subcutaneous- Market Size & Forecast 2019-2029F, USD Million
  • Oral- Market Size & Forecast 2019-2029F, USD Million

By Therapeutic Area

  • Oncology- Market Size & Forecast 2019-2029F, USD Million
  • Autoimmune Diseases- Market Size & Forecast 2019-2029F, USD Million
  • Infectious Diseases- Market Size & Forecast 2019-2029F, USD Million
  • Inflammatory Diseases- Market Size & Forecast 2019-2029F, USD Million
  • Others (Neurological Disorders, B-cell Malignancies, etc.) - Market Size & Forecast 2019-2029F, USD Million

Out of these, the oncology (cancer) segment has dominated the Global Next Generation Immunotherapy Market in recent years.

By End User

  • Hospitals- Market Size & Forecast 2019-2029F, USD Million
  • Specialty Clinics- Market Size & Forecast 2019-2029F, USD Million
  • Ambulatory Surgical Centres- Market Size & Forecast 2019-2029F, USD Million
  • Cancer Research Centres- Market Size & Forecast 2019-2029F, USD Million

Next Generation Immunotherapy Market Competitive Landscape

  • Bristol Myers Squibb
  • Regeneron Pharmaceuticals
  • MacroGenics
  • AbbVie Inc.
  • Pfizer Inc.
  • Novartis
  • Merck & Co., Inc.
  • AstraZeneca
  • Incyte Corporation
  • Eli Lilly and Company
  • Johnson and Johnson
  • Others

Next Generation Immunotherapy Market Development:

  • 2023: Boehringer Ingelheim and 3T Biosciences have formed a strategic collaboration to leverage 3T Biosciences' 3T-TRACE discovery platform and Boehringer Ingelheim's research expertise to develop next-generation cancer therapies. Boehringer Ingelheim will supply patient-derived TCR data to support 3T's antigen discovery using the TRACE platform, with 3T receiving initial payment and research backing.
  • 2022: Regeneron Pharmaceuticals and CytomX Therapeutics have formed a collaboration to develop conditionally-activated bispecific cancer therapies by combining CytomX's Probody platform and Regeneron's Veloci-Bi bispecific antibody development platform, with a focus on improving the therapeutic window and reducing off-target effects in immunotherapies.

Geographical Analysis:

By Region

  • North America
  • South America
  • Europe
  • Middle East & Africa
  • Asia-Pacific

Note: If you require specific information not covered in the current report, we can provide it through customized option

Why choose Us?

MarkNtel Advisors is a leading consulting, data analytics, and market research firm that provides an extensive range of strategic reports on diverse industry verticals. We being a qualitative & quantitative research company, strive to deliver data to a substantial & varied client base, including multinational corporations, financial institutions, governments, and individuals, among others.

For Media Inquiries, Please Contact:

Call: +1 628 895 8081 | +91 120 4278433

Email: sales@marknteladvisors.com

Sales Office: 564 Prospect St, B9, New Haven, Connecticut, USA-06511

Corporate Office: Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India